LianBio (NASDAQ:LIAN – Get Free Report) was down 2.1% on Friday . The stock traded as low as $0.20 and last traded at $0.20. Approximately 14,001 shares changed hands during trading, a decline of 99% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.20.
LianBio Stock Performance
The stock has a market capitalization of $21.61 million, a PE ratio of -0.25 and a beta of 0.23. The firm’s 50-day simple moving average is $0.21 and its two-hundred day simple moving average is $0.27.
About LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
Featured Articles
- Five stocks we like better than LianBio
- How to Capture the Benefits of Dividend Increases
- How to Build the Ultimate Everything ETF Portfolio
- Manufacturing Stocks Investing
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- The Significance of Brokerage Rankings in Stock Selection
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.
